Press Releases

Press Releases

Samsung Biologics Receives the 1st FDA Approval for its world largest Plant’s Production

Samsung Biologics Receives the 1st FDA Approval for its world largest Plant’s Production

 

- Licensed by US FDA regulatory for its second plant manufacture of Biologics Drug Substance for the first time

- Prove its global quality competitiveness such as biopharmaceutical quality and manufacturing systems with the world largest single plant with 150K liters of capacity in addition to its first plant

- Continue to prepare to receive more inspections for the Market Expansion 

 

 

 

[INCHEON, KOREA] October 11, 2017 ? Samsung Biologics announced today that on October 11, 2017 it has been licensed by the US FDA (Food and Drug Administration) for the first monoclonal antibody Drug Substance at its second plant, the world largest single plant.

 

With the first license of its second plant from the FDA, Samsung Biologics is now able to manufacture commercial Biologics Drug Substance at its second plant in addition to its first plant with 30K liters of capacity,

 

Compared to its first plant which took 25 months to get approval from FDA,
Samsung Biologics has received approval of its second plant from FDA in just 19 months since its GMP ready in 2016.

 

Samsung’s second plant with 152K liters is 5 times bigger and ten times more complicated than its first plant but Samsung saves 6 months to receive the first approval from FDA. And the size of its second plant is one and a half as big as global standard world-cup stadium.

 

Samsung Biologics has improved production efficiency through the installation of ten bioreactors firstly in the world, breaking industry stereotypes to install and operate only four or six bioreactors on a single bio-manufacturing plant.

 

With total of nine approvals now from FDA, EMA, and PMDA, Samsung has proved that all Samsung facilities are compliant with global GMP standards.

 

“We are eager to maintain and further improve our biopharmaceutical quality systems and manufacturing process in a GMP-certified manufacturing facility to provide high-quality products to our clients,” said TH Kim, CEO of Samsung Biologics. “We continue to be dedicated to exceeding the strictest of the quality standards and our customers’ expectations.”

 

Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality product for the patient.

 

Samsung Biologics has invested USD 740 million in its third plant with a bioreactor capacity of 180,000 liters and expects the construction will be completed by the 4th quarter of this year.

 

Once the third plant with advanced technology including 3D modeling is operational in 2018, Samsung Biologics is expected to have the world’s largest capacity for a biologics contract manufacturing organization(CMO), with a total production capacity of 362,000 liters.

 

Currently, Samsung Biologics has the production capacity of 182,000 liters through its first plant with 30K liters of capacity, which started full commercial operation in November 2015, and second plant with 152K liters of capacity, which started operation in February 2016.

 

                                                                                                                                           -  E N D -

 

 

 


About Samsung Biologics
Samsung Biologics is a world class full service provider of quality driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade, through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our end-to-end service includes cell line process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), clinical and commercial bulk cGMP manufacturing of drug substance and drug product including Quality Assurance, and Quality Control. Samsung Biologics is committed to meeting or exceeding worldwide regulatory compliance standards and support for our customers.
For additional information about the company, please visit http://www.Samsung Biologics.com.

 

 

 

 

 

 

Samsung Biologics Receives the 1st FDA Approval for its world largest Plant’s Production

 

- Licensed by US FDA regulatory for its second plant manufacture of Biologics Drug Substance for the first time

- Prove its global quality competitiveness such as biopharmaceutical quality and manufacturing systems with the world largest single plant with 150K liters of capacity in addition to its first plant

- Continue to prepare to receive more inspections for the Market Expansion 

 

 

 

[INCHEON, KOREA] October 11, 2017 – Samsung Biologics announced today that on October 11, 2017 it has been licensed by the US FDA (Food and Drug Administration) for the first monoclonal antibody Drug Substance at its second plant, the world largest single plant.

 

With the first license of its second plant from the FDA, Samsung Biologics is now able to manufacture commercial Biologics Drug Substance at its second plant in addition to its first plant with 30K liters of capacity,

 

Compared to its first plant which took 25 months to get approval from FDA, 
Samsung Biologics has received approval of its second plant from FDA in just 19 months since its GMP ready in 2016.

 

Samsung’s second plant with 152K liters is 5 times bigger and ten times more complicated than its first plant but Samsung saves 6 months to receive the first approval from FDA. And the size of its second plant is one and a half as big as global standard world-cup stadium.

 

Samsung Biologics has improved production efficiency through the installation of ten bioreactors firstly in the world, breaking industry stereotypes to install and operate only four or six bioreactors on a single bio-manufacturing plant.

 

With total of nine approvals now from FDA, EMA, and PMDA, Samsung has proved that all Samsung facilities are compliant with global GMP standards.

 

“We are eager to maintain and further improve our biopharmaceutical quality systems and manufacturing process in a GMP-certified manufacturing facility to provide high-quality products to our clients,” said TH Kim, CEO of Samsung Biologics. “We continue to be dedicated to exceeding the strictest of the quality standards and our customers’ expectations.”

 

Samsung Biologics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality product for the patient.

 

Samsung Biologics has invested USD 740 million in its third plant with a bioreactor capacity of 180,000 liters and expects the construction will be completed by the 4th quarter of this year.

 

Once the third plant with advanced technology including 3D modeling is operational in 2018, Samsung Biologics is expected to have the world’s largest capacity for a biologics contract manufacturing organization(CMO), with a total production capacity of 362,000 liters.

 

Currently, Samsung Biologics has the production capacity of 182,000 liters through its first plant with 30K liters of capacity, which started full commercial operation in November 2015, and second plant with 152K liters of capacity, which started operation in February 2016.

 

                                                                                                                                           -  E N D -

 

 

 


About Samsung Biologics
Samsung Biologics is a world class full service provider of quality driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade, through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our end-to-end service includes cell line process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), clinical and commercial bulk cGMP manufacturing of drug substance and drug product including Quality Assurance, and Quality Control. Samsung Biologics is committed to meeting or exceeding worldwide regulatory compliance standards and support for our customers. 
For additional information about the company, please visit http://www.Samsung Biologics.com.

 

 

 

 

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION